Philip Abraham, MD
Internal Medicine · Kittery, MENPI 1497750764
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $541 of the $881 with a category attached, or 61.4%. 7 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 39.7% of the total. Reporting peaked in 2022 at $386 and has fallen 86.8% since, to $51 in 2025. Among internal medicine clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 36 payments — averaging $24.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$350
- Olympus Corporation$255
- AbbVie$118
- Astellas Pharma US Inc$107
- Boehringer Ingelheim$19
- Ferring Pharmaceuticals Inc.$19
- plus $14 from 1 others
What the payments were for
- Consulting fees$25529%
- Food & beverage$54161%
- Education$8510%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $350 |
| Olympus Corporation | 1 | $255 |
| AbbVie | 6 | $118 |
| Astellas Pharma US Inc | 2 | $107 |
| Boehringer Ingelheim | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| GSK | 1 | $14 |
How this compares
$881 in reported general payments places this provider in the 90th percentile of 445 internal medicine providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 23 | $167,195 |
| EliquisApixaban | 56 | $70,441 |
| OzempicSemaglutide | 34 | $44,164 |
| LinzessLinaclotide | 40 | $28,851 |
| JardianceEmpagliflozin | 12 | $21,331 |
| TrulancePlecanatide | 14 | $18,717 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $18,175 |
| JanuviaSitagliptin Phosphate | 12 | $14,576 |
| Mesalamine | 17 | $4,216 |
| Rosuvastatin Calcium | 107 | $3,055 |
| Colestipol Hcl | 24 | $2,729 |
| Duloxetine Hcl | 32 | $2,353 |
| Pantoprazole Sodium | 125 | $2,273 |
| Budesonide DrBudesonide | 16 | $1,861 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $118 | $28,85140 claims |
| Boehringer IngelheimJardiance | $19 | $21,33112 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $350 | $18,71714 claims |
| GSKTrelegy Ellipta | $14 | $18,17513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 445 internal medicine providers in Maine.
Other internal medicine in Kittery
- Nananda ColPortland$124K
- Heidi DeblockPortland$27K
- Gene ChengAugusta$22K
- Elizabeth DennisWestbrook$17K
- Hassan AbouleishHoulton$15K
- Peter GuzzettiAugusta$11K
- Linford StillsonWestbrook$11K
- Peter LeightonBridgton$10K
- Tony VargheseBaltimore$8K
- Donald StricklandAugusta$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.